Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07845071
PHASE3

An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin

Sponsor: Adneuris Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety and effectiveness of cebranopadol in treating acute pain.

Official title: An Open-Label, Single-Arm, Multiple-Dose, Phase 3 Safety and Efficacy Study of Cebranopadol in Participants With Moderate to Severe Acute Pain With Surgical or Non-Surgical Origin

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

160

Start Date

2026-09-22

Completion Date

2027-02

Last Updated

2026-09-30

Healthy Volunteers

No

Conditions

Interventions

DRUG

Cebranopadol 400 ug

Participants receive Cebranopadol 400 mcg once per day for 14 days or until pain resolves, whichever occurs first.

Locations (15)

Adneuris Site 001115

Phoenix, Arizona, United States

Adneuris Site 001118

Riverside, California, United States

Adneuris Site 001119

Longmont, Colorado, United States

Adneuris Site 001122

Savannah, Georgia, United States

Adneuris Site 001123

O'Fallon, Illinois, United States

Adneuris Site 001125

Annapolis, Maryland, United States

Adneuris Site 001120

Oradell, New Jersey, United States

Adneuris Site 001124

Tulsa, Oklahoma, United States

Adneuris Site 001110

Bellaire, Texas, United States

Adneuris Site 001117

Forney, Texas, United States

Adneuris Site 001104

McAllen, Texas, United States

Adneuris Site 001116

Plano, Texas, United States

Adneuris Site 001111

San Antonio, Texas, United States

Adneuris Site 001121

San Antonio, Texas, United States

Adneuris Site 001101

Salt Lake City, Utah, United States